Related Experiment Videos
Combination medical therapy for symptomatic benign prostatic hyperplasia.
Stephen J. Savage1, Ann M. Spungen, Giuseppe Galea
1Department of Urology, The Mount Sinai School of Medicine, New York, New York.
The Canadian Journal of Urology
|April 18, 2001
Summary
Combination therapy with terazosin and finasteride significantly improves benign prostatic hyperplasia (BPH) symptoms more than monotherapy. This BPH treatment offers greater symptom relief for men.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Symptomatic BPH significantly impacts quality of life.
- Medical management options include alpha-blockers and 5-alpha-reductase inhibitors.
Purpose of the Study:
- To compare the efficacy of terazosin monotherapy, finasteride monotherapy, and combination therapy for symptomatic BPH.
- To evaluate treatment response using International Prostate Symptom Score (IPSS), peak urinary flow rate, and detrusor pressure.
Main Methods:
- 12-month randomized controlled trial involving men with symptomatic BPH.
- Patients received terazosin, finasteride, or both.
- Assessments included IPSS, peak urinary flow rate, prostate volume, and detrusor pressure at specified intervals.
Main Results:
- All treatment groups showed significant symptom score reduction (p<0.05).
- Combination therapy yielded greater IPSS reduction compared to monotherapy (p<0.05).
- Combination therapy also led to a greater decrease in detrusor pressure than finasteride alone (p<0.03).
Conclusions:
- Combined medical therapy with finasteride and terazosin offers superior symptom relief for BPH compared to monotherapy.
- Combination therapy may be a more effective treatment strategy for men with symptomatic BPH.